サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1317921

片頭痛治療薬市場：治療クラス、治療タイプ、投与経路、流通別-2023-2030年の世界予測

Migraine Drugs Market by Therapeutic Class, Treatment Type, Route of Administration, Distribution - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 182 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
片頭痛治療薬市場：治療クラス、治療タイプ、投与経路、流通別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

片頭痛治療薬の世界市場は、2023年に47億4,022万米ドル、CAGR15.81％で大きく成長し、2030年には132億6,564万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の片頭痛治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.片頭痛治療薬の世界市場規模および予測は？

2.予測期間中、世界の片頭痛治療薬市場を形成するCOVID-19の阻害要因と影響は？

3.片頭痛治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.片頭痛治療薬の世界市場における競争戦略は？

5.片頭痛治療薬の世界市場における技術動向と規制の枠組みは？

6.片頭痛治療薬の世界市場における主要ベンダーの市場シェアは？

7.片頭痛治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 片頭痛の発生率の増加と新薬の発売
      • 女性人口の増加とタバコ消費量の増加
      • 電気神経刺激装置などのヘルスケア施設の進歩
    • 抑制要因
      • 片頭痛治療薬に関連する副作用
    • 機会
      • 片頭痛薬に対するサポート的な償還ポリシー
      • 製薬分野における協力とパートナーシップのプログラムの増加
    • 課題
      • 代替療法の利用可能性と規制上の課題
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 片頭痛治療薬市場セラピークラス別

  • 吐き気止め薬
    • クロルプロマジン
    • メトクロプラミド
    • プロクロルペラジン
  • 血圧を下げる薬
    • Β遮断薬
    • カルシウムチャネルブロッカー
  • 麦角
    • ジヒドロエルゴタミン
    • エルゴタミン
    • ラスミディタン
  • オピオイド薬
    • オキシコンチン
    • パーコセット
    • バイコディン
  • 鎮痛剤
    • アスピリン
    • イブプロフェン
  • トリプタン製剤
    • リザトリプタン
    • スマトリプタン

第7章 片頭痛治療薬市場治療タイプ別

  • 流産
  • 予防

第8章 片頭痛治療薬市場：投与経路別

  • 注射可能
  • 点鼻薬
  • オーラル

第9章 片頭痛治療薬市場配信別

  • 病院を拠点とする薬局
  • オンライン薬局
  • 小売薬局

第10章 南北アメリカの片頭痛治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の片頭痛治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの片頭痛治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第14章 掲載企業一覧

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. MIGRAINE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. MIGRAINE DRUGS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
  • FIGURE 5. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2022 VS 2030 (%)
  • FIGURE 6. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 7. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 8. MIGRAINE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. MIGRAINE DRUGS MARKET DYNAMICS
  • FIGURE 10. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. MIGRAINE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MIGRAINE DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MIGRAINE DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MIGRAINE DRUGS MARKET SIZE, BY PROCHLORPERAZINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MIGRAINE DRUGS MARKET SIZE, BY BETA-BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MIGRAINE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 15. MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. MIGRAINE DRUGS MARKET SIZE, BY OXYCONTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. MIGRAINE DRUGS MARKET SIZE, BY PERCOCET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. MIGRAINE DRUGS MARKET SIZE, BY VICODIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 25. MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. MIGRAINE DRUGS MARKET SIZE, BY ASPIRIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 29. MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MIGRAINE DRUGS MARKET SIZE, BY ABORTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. MIGRAINE DRUGS MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. MIGRAINE DRUGS MARKET SIZE, BY HOSPITALS BASED PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. MIGRAINE DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. MIGRAINE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 247. DENMARK MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 257. EGYPT MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 267. FINLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 277. FRANCE MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 287. GERMANY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 297. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 307. ITALY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 317. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 327. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 328. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 329. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 337. NORWAY MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 338. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 339. NORWAY MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 347. POLAND MIGRAINE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 348. POLAND MIGRAINE DRUGS MARKET SIZE, BY ANTI-NAUSEA DRUG, 2018-2030 (USD MILLION)
  • TABLE 349. POLAND MIGRAINE DRUGS MARKET SIZE, BY BLOOD PRESSURE LOWERING MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 350. POLAND MIGRAINE DRUGS MARKET SIZE, BY ERGOTS, 2018-2030 (USD MILLION)
  • TABLE 351. POLAND MIGRAINE DRUGS MARKET SIZE, BY OPIOID MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 352. POLAND MIGRAINE DRUGS MARKET SIZE, BY PAIN RELIEVER, 2018-2030 (USD MILLION)
  • TABLE 353. POLAND MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2030 (USD MILLION)
  • TABLE 354. POLAND MIGRAINE DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 355. POLAND MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND MIGRAINE DR
目次
Product Code: MRR-036C5CF3A821

The Global Migraine Drugs Market is forecasted to grow significantly, with a projected USD 4,740.22 million in 2023 at a CAGR of 15.81% and expected to reach a staggering USD 13,265.64 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Migraine Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Migraine Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapeutic Class, market is studied across Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, Pain Reliever, and Triptans. The Anti-Nausea Drug is further studied across Chlorpromazine, Metoclopramide, and Prochlorperazine. The Blood Pressure Lowering Medication is further studied across Beta-Blocker and Calcium Channel Blocker. The Ergots is further studied across Dihydroergotamines, Ergotamine, and Lasmiditan. The Opioid Medication is further studied across OxyContin, Percocet, and Vicodin. The Pain Reliever is further studied across Aspirin and Ibuprofen. The Triptans is further studied across Rizatriptan and Sumatriptan. The Ergots is projected to witness significant market share during forecast period.

Based on Treatment Type, market is studied across Abortive and Preventive. The Preventive is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Injectable, Nasal Spray, and Oral. The Oral is projected to witness significant market share during forecast period.

Based on Distribution, market is studied across Hospitals Based Pharmacy, Online Pharmacy, and Retail Pharmacy. The Retail Pharmacy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Migraine Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Migraine Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Migraine Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Migraine Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Migraine Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Migraine Drugs Market?

6. What is the market share of the leading vendors in the Global Migraine Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Migraine Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Migraine Drugs Market, by Therapeutic Class, 2022 vs 2030
  • 4.3. Migraine Drugs Market, by Treatment Type, 2022 vs 2030
  • 4.4. Migraine Drugs Market, by Route of Administration, 2022 vs 2030
  • 4.5. Migraine Drugs Market, by Distribution, 2022 vs 2030
  • 4.6. Migraine Drugs Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidence of migraines and launch of new drugs
      • 5.1.1.2. Rise in female population and increase in cigarette consumption
      • 5.1.1.3. Advancements in healthcare facilities such as electrical nerve stimulation devices
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with migraine drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Supportive reimbursement policies for migraine medications
      • 5.1.3.2. Increased programmes of collaboration and partnership in the pharmaceutical sector
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative therapies and regulatory challenges
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Migraine Drugs Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Anti-Nausea Drug
    • 6.2.1. Chlorpromazine
    • 6.2.2. Metoclopramide
    • 6.2.3. Prochlorperazine
  • 6.3. Blood Pressure Lowering Medication
    • 6.3.1. Beta-Blocker
    • 6.3.2. Calcium Channel Blocker
  • 6.4. Ergots
    • 6.4.1. Dihydroergotamines
    • 6.4.2. Ergotamine
    • 6.4.3. Lasmiditan
  • 6.5. Opioid Medication
    • 6.5.1. OxyContin
    • 6.5.2. Percocet
    • 6.5.3. Vicodin
  • 6.6. Pain Reliever
    • 6.6.1. Aspirin
    • 6.6.2. Ibuprofen
  • 6.7. Triptans
    • 6.7.1. Rizatriptan
    • 6.7.2. Sumatriptan

7. Migraine Drugs Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Abortive
  • 7.3. Preventive

8. Migraine Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Nasal Spray
  • 8.4. Oral

9. Migraine Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. Hospitals Based Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Migraine Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Migraine Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Migraine Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing